- 首頁
- App 分析
- eMIMS Plus
- eMIMS Plus Vs. ARF RHD Guidelines
eMIMS Plus 與 ARF RHD Guidelines 使用情況與統計
Including much more information than the first eMIMS of 17 years ago, and with the ability to find it faster than ever, New eMIMS has been developed to meet the needs of our current users.
New eMIMS continues to be the trusted resource you know and love and remains your complete guide to Product Information, Consumer Medicine Information, Product Images, Drug Interactions and PBS restrictions and pricing for all registered medicines in Australia.
- Apple App Store
- 免費版
- 醫療
商店排名
- -
Rheumatic heart disease represents the greatest cardiovascular inequality between Indigenous and non-Indigenous Australians. From 2013 to 2017, 94% of all new rheumatic heart disease cases were among Aboriginal and Torres Strait Islander people.
This app assists clinicians in the diagnosis and management of acute rheumatic fever and rheumatic heart disease. Published by RHDAustralia, based at Menzies School of Health Research, the app contains the most up-to-date evidence and details various aspects of patient care. It is informed by the 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (3rd edition), available at https://www.rhdaustralia.org.au/arf-rhd-guideline. The app also contains an ARF Diagnosis Calculator which embeds the lengthy and complex ARF diagnosis algorithms into a series of simple questions that assist clinicians to diagnose ARF. The algorithms comply with the 2015 American Heart Association revision of the Jones Criteria for diagnosis of ARF, which has been endorsed by the World Heart Federation, making the Diagnosis Calculator now able to be used globally.
- Apple App Store
- 免費版
- 醫療
商店排名
- -
eMIMS Plus與 ARF RHD Guidelines 比較排名
比較過去 28 天的 eMIMS Plus 排名趨勢與 ARF RHD Guidelines
排名
無可用數據
各國 eMIMS Plus vs. ARF RHD Guidelines 排名比較
比較過去 28 天的 eMIMS Plus 排名趨勢與 ARF RHD Guidelines
所有類別
無可用數據
醫療
使用我們的免費試用版,與所有網站進行比較
eMIMS Plus VS.
ARF RHD Guidelines
12月 12, 2024